Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy
- 1st Edition, Volume 181 - June 12, 2021
- Imprint: Academic Press
- Editor: Vijai Singh
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 3 2 3 - 1
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 3 2 4 - 8
Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy, presents the collation of chapters written by eminent scientists worldwide. CRISPR-Cas9 is a key technolog… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteReprogramming the Genome: CRISPR-Cas-based Human Disease Therapy, presents the collation of chapters written by eminent scientists worldwide. CRISPR-Cas9 is a key technology for targeted genome editing and regulation in a number of organisms including mammalian cells. It is a rapid, simple, and cost-effective solution. CRISPR-Cas system has recently gained much scientific and public attention. This volume covers CRISPR-Cas9 based mammalian genome editing, creating disease models, cancer therapy, neurological, heredity, blood disorders, defective gene correction, stem cells therapy, epigenetic modifications, patents, ethics, biosafety and regulatory issues challenges and opportunities. This book is a key source of information on mammalian genome editing available in a single volume. This book will be useful for beginners in mammalian genome editing and also students, researchers, scientists, policymakers, clinicians and stakeholders interested in genome editing in several areas.
- Offers basic understanding and a clear picture of mammalian genome editing through CRISPR-Cas systems
- Discusses how to create mammalian disease models, stem cell modification, epigenetic modifications, correction of defective gene in blood disorders, heredity, neurological disorders and many more
- Discusses the application of CRISPR-Cas9 systems in basic sciences, biomedicine, molecular biology, translational sciences, neurobiology, neurology, cancer, stem cells, and many more
A valuable sources of information for not only beginner in area of genome engineering area, but also researchers, students, scientists, clinicians, stakeholders, policy makers and practitioners and many more
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: An introduction to CRISPR-Cas systems for reprogramming the genome of mammalian cells
- Abstract
- 1: Introduction
- 2: Development of genome engineering technology
- 3: Progress and applications of CRISPR-Cas9 system
- 4: Conclusion and future remarks
- Acknowledgments
- Chapter Two: CRISPR-Cas systems for genome editing of mammalian cells
- Abstract
- 1: Introduction
- 2: CRISPR-Cas9 system for genome editing of mammalian cells
- 3: CRISPR-Cas9 for creating cell and animal models
- 4: CRISPR-Cas9 system for improving mammalian health
- 5: Base editing in mammalian cells
- 6: Conclusion and future remarks
- Acknowledgment
- Chapter Three: Genome-wide detection and analysis of CRISPR-Cas off-targets
- Abstract
- 1: Introduction
- 2: GS-preprocess: A GUIDE-seq data preprocessing tool
- 3: Vignette
- 4: Conclusion
- Chapter Four: CRISPR-based diagnostics for detection of pathogens
- Abstract
- 1: Introduction
- 2: Progress and development of CRISPR-Cas systems
- 3: CRISPR-Cas9 mediated diagnostics
- 4: CRISPR-Cas12 mediated diagnostics
- 5: CRISPR-Cas13 mediated diagnostics
- 6: Conclusion and future remarks
- Acknowledgments
- Chapter Five: Creating cell lines for mimicking diseases
- Abstract
- 1: Introduction: Concepts and characteristics of cell lines
- 2: Genome editing of cell lines: The basics
- 3: Edited cell lines can mimic diseases in vitro: From diabetes to lysosomal diseases
- 4: Conclusions and future remarks
- Chapter Six: Modulating Cas9 activity for precision gene editing
- Abstract
- 1: Introduction
- 2: Targeted gene editing
- 3: A major hurdle: The off-targeting issue in gene editing
- 4: Increasing specificity and on-target activity of Cas9
- 5: Engineering of Cas9 PAM preferences
- 6: Modulating Cas9 availability
- 7: Cas9 as a drug target for precision in gene editing
- 8: Conclusions and future remarks
- Acknowledgments
- Chapter Seven: CRISPR-Cas9 in cancer therapeutics
- Abstract
- 1: Introduction
- 2: Gene editing technologies: A shift in the paradigm
- 3: Applications of CRISPR in cancer drug development
- 4: Challenges to the clinic
- 5: Conclusions
- Chapter Eight: CRISPR-Cas9 for treating hereditary diseases
- Abstract
- 1: Introduction
- 2: Types of genetic diseases
- 3: Applications of CRISPR-Cas technology in other hereditary diseases
- 4: Conclusions and future perspectives
- Acknowledgments
- Chapter Nine: CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals
- Abstract
- 1: Introduction
- 2: Gene correction and related strategies
- 3: Strategies to improve efficiency of homology-mediated gene editing
- 4: Delivery methods of the CRISPR/Cas9 gene editing system
- 5: Application of CRISPR to the correction of defective genes in humans and other mammals
- 6: Conclusions and future perspectives
- Acknowledgments
- Author's contribution
- Conflict of interests
- Chapter Ten: Recent advances in stem cells and gene editing: Drug discovery and therapeutics
- Abstract
- 1: Introduction
- 2: Biomedical characteristics of stem cells
- 3: Advances in gene editing technologies
- 4: Type II CRISPR system
- 5: Biomedical importance of CRISPR/CAS-induced stem cells
- 6: Therapeutic stem cells generated using CRISPR/Cas platforms
- 7: Conclusion
- Acknowledgment
- Chapter Eleven: Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms
- Abstract
- 1: Introduction
- 2: Applications of genome-edited stem cells in disease modeling
- 3: Concluding remarks
- Acknowledgments
- Chapter Twelve: Genome editing in cardiovascular diseases
- Abstract
- 1: Introduction
- 2: Use of CRISPR-Cas9 system in the cardiovascular diseases
- 3: Hypertrophic cardiomyopathy
- 4: Dilated cardiomyopathy
- 5: Arrhythmogenic cardiomyopathy
- 6: Conclusion and future perspectives
- Chapter Thirteen: CRISPR/Cas9 in epigenetics studies of health and disease
- Abstract
- 1: Introduction
- 2: Why epigenetic modification is required?
- 3: History of epigenetics
- 4: Types of Epigenetic modification
- 5: How the role of epigenetics is important about the different physiological process?
- 6: Clinical use of epigenetics studies
- 7: CRISPR/Cas9 mediated epigenetic therapeutics
- 8: Applications of dCas9 mediated epigenome editing
- 9: Limitation
- 10: Conclusion and future perspectives
- Chapter Fourteen: Patents, ethics, biosafety and regulation using CRISPR technology
- Abstract
- 1: Introduction
- 2: Current and recent development of CRISPR technology on mammalian systems
- 3: Current patent landscape in CRISPR technology on mammalian systems
- 4: Comparative analysis of CRISPR patent landscape between US, Europe and other developing countries
- 5: Ethics of CRISPR technology on mammalian systems-including research, patent and technology transfer
- 6: Biosafety and regulation in CRISPR technology on mammalian system
- 7: Conclusion
- Index
- Edition: 1
- Volume: 181
- Published: June 12, 2021
- Imprint: Academic Press
- No. of pages: 390
- Language: English
- Hardback ISBN: 9780323853231
- eBook ISBN: 9780323853248
VS
Vijai Singh
Dr Vijai Singh is a Professor and Dean (Research & Innovation) at School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. He was an Associate Professor in the Department of Biosciences, School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. Prior this this, he was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, India and also an Assistant Professor in the Department of Biotechnology at the Invertis University, Bareilly, India. Prior to that, he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He received his Ph.D. in Biotechnology from the National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on building novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally, his laboratory is working on CRISPR-Cas9 tools for genome editing. He has more than 11 years of research and teaching experience in synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has published 100 articles, 70 chapters, 15 books and 3 patents. He serves as an associate editor, editorial board member, and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.
Affiliations and expertise
Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, IndiaRead Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy on ScienceDirect